Premier Graphene (BIEI) 10-Q 23 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 21, 2018
Document And Entity Information
Entity Registrant Name	PREMIER BIOMEDICAL INC
Entity Central Index Key	1,515,740
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		747,306,550
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,018

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash	$ 79,221	$ 83,704
Accounts receivable		312
Inventory	79,410	84,763
Other current assets	33,327	34,824
Total current assets	191,958	203,603
Property and equipment, net	6,916	5,478
Total assets	198,874	209,081
Current liabilities:
Accounts payable	346,856	346,814
Accounts payable, related parties	40,904	41,382
Accrued interest	9,125	5,840
Convertible notes payable, net of discounts of $40,222 and $30,010 at March 31, 2018 and December 31, 2017, respectively, currently in default	154,778	169,990
Derivative liabilities	1,574,343	2,255,781
Total current liabilities	2,126,006	2,819,807
Total liabilities	2,126,006	2,819,807
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 2,000,000 shares issued and outstanding at March 31, 2018 and December 31, 2017	2,000	2,000
Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 747,306,550 and 637,840,677 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	7,473	6,378
Additional paid in capital	13,825,883	13,435,903
Subscriptions payable, consisting of -0- and 63,675,678 shares at March 31, 2018 and December 31, 2017, respectively		273,805
Accumulated deficit	(15,762,488)	(16,328,812)
Total stockholders' equity (deficit)	(1,927,132)	(2,610,726)
Total liabilities and stockholders' equity (deficit)	$ 198,874	$ 209,081

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current liabilities:
Convertible notes payable, net of discounts	$ 40,222	$ 30,010
Stockholders' equity (deficit):
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized shares	10,000,000	10,000,000
Preferred stock, issued shares	2,000,000	2,000,000
Preferred stock, outstanding shares	2,000,000	2,000,000
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, authorized shares	1,000,000,000	1,000,000,000
Common stock, issued shares	747,306,550	637,840,677
Common stock, outstanding shares	747,306,550	637,840,677
Subscriptions payable, shares	0	63,675,678

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Condensed Consolidated Statements Of Operations
Revenue	$ 10,395
Cost of goods sold	6,058
Gross profit	4,337
Operating expenses:
General and administrative	34,492	33,059
Professional fees	39,616	41,147
Total operating expenses	74,108	74,206
Net operating loss	(69,771)	(74,206)
Other income (expense):
Interest expense	(64,145)	(152,747)
Change in derivative liabilities	700,240	(5,100,091)
Equity in losses of investment in joint venture		(2,058)
Total other income (expense)	636,095	(5,254,896)
Net income (loss)	$ 566,324	$ (5,329,102)
Weighted average number of common shares outstanding - basic	718,803,900	401,283,532
Weighted average number of common shares outstanding - fully diluted	721,796,400	402,283,532
Net loss per share - basic	$ 0	$ (0.01)
Net loss per share - fully diluted	$ 0	$ (0.01)

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ 566,324	$ (5,329,102)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	591	528
Equity in losses of joint venture investment		2,058
Change in fair market value of derivative liabilities	(700,240)	5,100,091
Amortization of debt discounts	60,860	149,456
Decrease (increase) in assets:
Accounts receivable	312
Inventory	5,353
Other current assets	1,497	1,922
Increase (decrease) in liabilities:
Accounts payable	42	(42,297)
Accounts payable, related parties	(478)	236
Accrued interest	3,285	2,691
Accrued interest, related parties		600
Net cash used in operating activities	(62,454)	(113,817)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(2,029)
Investment in joint venture		(2,058)
Net cash used in investing activities	(2,029)	(2,058)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of stock, net of offering costs		285,000
Proceeds from sale of stock on equity line of credit		18,323
Proceeds from convertible notes payable	60,000
Net cash provided by financing activities	60,000	303,323
NET CHANGE IN CASH	(4,483)	187,448
CASH AT BEGINNING OF PERIOD	83,704	22,437
CASH AT END OF PERIOD	79,221	209,885
SUPPLEMENTAL INFORMATION:
Interest paid
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Value of debt discounts	60,000
Value of derivative adjustment due to debt conversions	52,270	229,043
Value of shares issued for conversion of debt	$ 65,000	$ 323,197

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Note 1 - Basis of Presentation and Significant Accounting Policies	Basis of Presentation The accompanying unaudited, condensed financial statements of Premier Biomedical, Inc. (“the Company”) have been prepared pursuant to rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, these statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. It is suggested that these statements be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Patent Rights and Applications Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated. Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Basic and Diluted Loss Per Share Basic earnings per share (“EPS”) are computed by dividing net income (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted EPS is computed by dividing net income by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include stock options, warrants and restricted stock. The number of potential common shares outstanding relating to stock options, warrants and restricted stock is computed using the treasury stock method. The reconciliation of the denominators used to calculate basic EPS and diluted EPS for the three months ended March 31, 2018 and 2017 are as follows: For the Three Months Ended March 31, 2018 2017 Weighted average common shares outstanding – basic 718,803,900 401,283,532 Plus: Potentially dilutive common shares: Stock options and warrants 2,992,500 - Weighted average common shares outstanding – diluted 721,796,400 401,283,532 For the three months ended March 31, 2017, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Stock options and warrants excluded from the calculation of diluted EPS because their effect was anti-dilutive were 61,440,000 and 110,690,004 as of March 31, 2018 and 2017, respectively. Stock-Based Compensation Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company had no stock based compensation issuances during the three months ended March 31, 2018 and 2017. Revenue Recognition Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales commenced on July 5, 2017 with the termination of our joint venture and are recognized upon shipment of goods, which are typically paid for at the time of order. Advertising and Promotion All costs associated with advertising and promoting products are expensed as incurred. These expenses were $9,925 and $67,216 for the three months ended March 31, 2018 and 2017, respectively. Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Recent Accounting Pronouncements Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the three months ended March 31, 2018 and 2017, or the twelve months ended December 31, 2017. In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2017-09 , Compensation — Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-9 No other new accounting pronouncements, issued or effective during the three months ended March 31, 2018, have had or are expected to have a significant impact on the Company’s financial statements.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Note 2 - Going Concern	As shown in the accompanying financial statements, the Company has no revenues, incurred net losses from operations resulting in an accumulated deficit of $15,762,488, and had negative working capital of ($1,934,048) at March 31, 2018. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. The financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Related Parties

Related Parties	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Note 3 - Related Parties	Accounts Payable The Company owed $39,116 and $40,195 as of March 31, 2018 and December 31, 2017, respectively, to entities owned by the Chairman of the Board of Directors. The amounts are related to patent costs and reimbursable expenses paid by the Chairman on behalf of the Company. The Company owed $713 as of March 31, 2018 and December 31, 2017, to the Company’s CEO for reimbursable expenses. The Company owed $1,075 and $478 as of March 31, 2018 and December 31, 2017, respectively, amongst members of the Company’s Board of Directors for reimbursable expenses.

Subsidiary Formation

Subsidiary Formation	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Note 4 - Subsidiary Formation	On September 14, 2017, we formed Premier Biomedical Pain Relief Meds, LLC as a wholly-owned Nevada limited liability company. On January 1, 2018, we contributed our pain management assets to this entity and continued our pain management operations within this new subsidiary.

Patent Rights and Applications

Patent Rights and Applications	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Note 5 - Patent Rights and Applications	The Company amortizes its patent rights and applications on a straight line basis over the expected useful technological or economic life of the patents, which is typically 17 years from the legal approval of the patent applications when there is probable future economic benefits associated with the patent. The Company has elected to expense all of their patent rights and application costs due to difficulties associated with having to prove the value of their future economic benefits. All patent applications are currently pending and the Company has no patents that have yet been approved. It is the Company’s policy that it performs reviews of the carrying value of its patent rights and applications on an annual basis. On March 4, 2015, we entered into a Patent License Agreement (“PLA”) with the University of Texas at El Paso (“UTEP”) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto. On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, “Anti-CTLA-4 Blockade” (the “Application”) under the definition of “Patent Rights” as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Note 6 - Fair Value of Financial Instruments	Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of March 31, 2018 and December 31, 2017, respectively: Fair Value Measurements at March 31, 2018 Level 1 Level 2 Level 3 Assets Cash $ 79,221 $ - $ - Total assets 79,221 - - Liabilities Convertible notes payable 154,778 Derivative liabilities - - 1,574,343 Total liabilities - 154,778 1,574,343 $ 79,221 $ (154,778 ) $ (1,574,343 ) Fair Value Measurements at December 31, 2017 Level 1 Level 2 Level 3 Assets Cash $ 83,704 $ - $ - Total assets 83,704 - - Liabilities Convertible note payable, net of discounts - 169,990 - Derivative liabilities - - 2,255,781 Total liabilities - 169,990 2,255,781 $ 83,704 $ (169,990 ) $ (2,255,781 ) The fair values of our related party debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the three months ended March 31, 2018 or the year ended December 31, 2017.

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Note 7 - Convertible Notes Payable	Convertible notes payable consist of the following at March 31, 2018 and December 31, 2017, respectively: March 31, December 31, 2018 2017 On March 1, 2018, the Company received proceeds of $30,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on May 31, 2018 (“First Red Diamond Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. $ 30,000 $ - On March 1, 2018, the Company received proceeds of $30,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on May 31, 2018 (“First SEG-RedaShex Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. 30,000 - On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second Diamond Rock Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default. 50,000 50,000 On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second SEG Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $10,000 of principal was converted into 5,208,333 shares of common stock on October 31, 2017, and the remaining $40,000 of principal was converted into 26,559,426 shares of common stock on January 29, 2018. - 40,000 On August 8, 2017, the Company entered into an exchange agreement with Diamond Rock, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First Diamond Rock Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $15,000 of principal was converted into an aggregate of 7,812,500 shares of common stock at various dates between November 6, 2017 and November 13, 2017. Currently in default. 35,000 35,000 On August 8, 2017, the Company entered into an exchange agreement with The Special Equities Group, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First SEG Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default. 50,000 50,000 On August 8, 2017, the Company entered into an exchange agreement with RDW Capital, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First RDW Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $25,000 of principal was converted into 13,157,895 shares of common stock on October 31, 2017, and the remaining $25,000 of principal was converted into 19,230,769 shares of common stock on January 3, 2018. - 25,000 Total convertible notes payable, currently in default 195,000 200,000 Less unamortized derivative discounts: 40,222 30,010 Convertible notes payable 154,778 169,990 Less: current portion 154,778 169,990 Convertible notes payable, less current portion $ - $ - The Company recognized interest expense for the three months ended March 31, 2018 and 2017, respectively, as follows: March 31, March 31, 2018 2017 Interest on convertible notes $ 3,285 $ 2,691 Interest on related party loans 1,800 600 Derivative discounts 60,860 149,456 Total interest expense $ 64,145 $ 152,747

Derivative Liabilities

Derivative Liabilities	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Note 8 - Derivative Liabilities	As discussed in Note 7 under Convertible Notes Payable, the Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted and all additional convertible debentures and warrants are included in the value of the derivative. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative liabilities on the issuance date. The fair values of the Company’s derivative liabilities were estimated at the issuance date and are revalued at each subsequent reporting date, using a lattice model. The Company recognized current derivative liabilities of $1,574,343 and $2,255,781 at March 31, 2018 and December 31, 2017, respectively. The change in fair value of the derivative liabilities resulted in a gain of $700,240 and a loss of $5,100,091 for the three months ended March 31, 2018 and 2017, respectively, which has been reported within other expense in the statements of operations. The gain of $700,240 for the three months ended March 31, 2018 consisted of a gain of $718,750 due to the value attributable to the warrants and a net loss in market value of $18,510 on the convertible notes. The loss of $5,100,091 for the three months ended March 31, 2017 consisted of a loss of $4,945,782 due to the value attributable to the warrants, a loss of $147,088 in market value of the warrants and a net loss in market value of $7,221 on the convertible notes. The following is a summary of changes in the fair market value of the derivative liability during the three months ended March 31, 2018 and the year ended December 31, 2017, respectively: Derivative Liability Total Balance, December 31, 2016 $ 221,822 Increase in derivative value due to issuances of convertible promissory notes 221,515 Increase in derivative value attributable to tainted warrants 7,103,444 Decrease in derivative value attributable to exchange of warrants (3,766,437 ) Change in fair market value of derivative liabilities due to the mark to market adjustment (1,221,021 ) Debt conversions (303,542 ) Balance, December 31, 2017 $ 2,255,781 Increase in derivative value due to issuances of convertible promissory notes 71,072 Change in fair market value of derivative liabilities due to the mark to market adjustment (700,240 ) Debt conversions (52,270 ) Balance, March 31, 2018 $ 1,574,343 Key inputs and assumptions used to value the convertible debentures and warrants issued during the three months ended March 31, 2018: · Stock price ranging from $0.0063 to $0.0033 during these periods would fluctuate with projected volatility. · The notes convert with variable conversion prices and fixed conversion prices (tainted notes). · An event of default would occur -0-% of the time, increasing 2% per month to a maximum of 10%. · The projected annual volatility curve for each valuation period was based on the historical annual volatility of the company in the range of 146% - 313%. · The Company would redeem the notes -0-% of the time, increasing 1% per month to a maximum of 5%. · All notes are assumed to be extended at maturity by 2 years – the time required to convert out this volume of stock. · The holders of the securities would automatically convert midway through to maturity on a monthly basis based on ownership and trading volume limitations. · A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%. · The monthly trading volume would average $968,718 to $1,011,107 and would increase at 1% per month. · The stock price would fluctuate with the Company projected volatility using a random sampling (450,000 iterations for each valuation) from a normal distribution. The stock price of the underlying instrument is modelled such that it follows a geometric Brownian motion with constant drift and volatility. · The Holder would exercise the warrants after one trading day as they become exercisable (at issuance) at target prices of 3 to 5 times the projected reset price or higher. · Reset events were projected to occur by 3/31/18 and 12/31/18 – the reset provision ends 3/30/19 and the option expires 3/30/20. · The stock price would fluctuate with an annual volatility. The projected annual volatility curve for each valuation period was based on the historical annual volatility of the company and the term remaining in the range 253% - 191%. · The Holder would exercise the warrant at maturity in 2020 if the stock price was above the reset exercise price.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Note 9 - Commitments and Contingencies	Collaborative Patent License Agreements On May 9, 2012, the Company entered into a Collaborative Agreement with the University of Texas at El Paso. Pursuant to the terms of the Agreement, the Company will work jointly with the University to develop a series of research and development programs around its sequential-dialysis technology in the areas of Alzheimer's Disease, Traumatic Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), Blood Sepsis, Cancer, Heart Attacks and Strokes. The programs will utilize the facilities at one or more of the University of Texas’ campuses. The Company will pay the University’s actual overhead for the projects, plus a negotiated facility and administration overhead expense, and 10% of all gross revenues associated with the sale, license and/or royalties of all products and treatment procedures directly affiliated with programs. Intellectual property jointly invented and developed as a result of the projects will be owned jointly by the University and the Company. The Agreement has an initial term of five (5) years, and is renewable upon mutual agreement of the parties. On March 4, 2015, we entered into a Patent License Agreement (PLA) with the University of Texas at El Paso (UTEP) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto. On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, “Anti-CTLA-4 Blockade” (the “Application”) under the definition of “Patent Rights” as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System. On October 31, 2017 we entered into an Agreement, Final Payment under Contract, and Release of all Claims, whereby we agreed to pay them a total of $326,336 arising out of the research and development agreements with an initial payment of $22,211, and monthly payments of varying amounts between $5,000 and $20,000 thereafter for twenty eight months until the balance is paid in full. Subject to the compliance of all terms, the intellectual property rights established and arising out of the collaborative agreements remain in full force and effect and the parties agreed to a mutual release upon the final contracted payment. The full amount of the liability has been recognized as an accounts payable as of the date of this filing.

Changes in Stockholders_ Equity

Changes in Stockholders’ Equity (Deficit)	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Note 10 – Changes in Stockholders’ Equity (Deficit)	Convertible Preferred Stock, Series A The Company has 10,000,000 authorized shares of Preferred Stock, of which 2,000,000 shares of $0.001 par value Series A Convertible Preferred Stock (“Series A Preferred Stock”) have been designated. Each share of Series A Preferred Stock is convertible, at the option of the holder thereof, at any time after the issuance of such share into one (1) fully paid and non-assessable share of Common Stock. Each outstanding share of Series A Preferred Stock is entitled to one hundred (100) votes per share on all matters to which the shareholders of the Corporation are entitled or required to vote. The Company shall reserve and keep available out of its authorized but unissued shares of Common Stock such number of shares sufficient to effect the conversions. Common Stock The Company has one billion authorized shares of $0.00001 par value Common Stock, as increased pursuant to an amendment to the articles of incorporation on February 9, 2016. Common Stock Issuances for Debt Conversions On January 29, 2018, the Company issued 26,559,426 shares of common stock pursuant to the conversion of $40,000 of principal from the Second SEG Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On January 3, 2018, the Company issued 19,230,769 shares of common stock pursuant to the conversion of $25,000 of principal from the First RDW Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Issuances on Subscriptions Payable On various dates from January 17, 2018 through February 13, 2018, the Company issued a total of 63,675,678 shares to The Special Equities Group and DiamondRock, LLC as compensation valued at $273,805 awarded on December 6, 2017.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Note 11 - Income Taxes	The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the three months ended March 31, 2018, and the year ended December 31, 2017, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At March 31, 2018, and December 31, 2017, the Company had approximately $4,930,000 and $4,860,000 of federal net operating losses, respectively. The net operating loss carry forwards, if not utilized, will begin to expire in 2031. The components of the Company’s deferred tax asset are as follows: March 31, December 31, 2018 2017 Deferred tax assets: Net operating loss carry forwards $ 1,725,000 $ 1,701,000 Net deferred tax assets before valuation allowance $ 1,725,000 $ 1,701,000 Less: Valuation allowance (1,725,000 ) (1,701,000 ) Net deferred tax assets $ - $ - Based on the available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at March 31, 2018, and December 31, 2017, respectively. A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and state statutory income tax rate to pre-tax loss is as follows: March 31, December 31, 2018 2017 Federal and state statutory rate 21 % 35 % Change in valuation allowance on deferred tax assets (21) % (35) % In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Note 12 - Subsequent Events	Securities Purchase Agreement On April 24, 2018, we received $60,000 from two investors from the sale of 8% interest bearing; unsecured convertible promissory notes maturing on May 31, 2018. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.

Basis of Presentation and Sig18

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Basis Of Presentation And Significant Accounting Policies Policies
Basis of Presentation	The accompanying unaudited, condensed financial statements of Premier Biomedical, Inc. (“the Company”) have been prepared pursuant to rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, these statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. It is suggested that these statements be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents.
Patent Rights and Applications	Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated.
Fair Value of Financial Instruments	Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Basic and Diluted Loss Per Share	Basic earnings per share (“EPS”) are computed by dividing net income (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted EPS is computed by dividing net income by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include stock options, warrants and restricted stock. The number of potential common shares outstanding relating to stock options, warrants and restricted stock is computed using the treasury stock method. The reconciliation of the denominators used to calculate basic EPS and diluted EPS for the three months ended March 31, 2018 and 2017 are as follows: For the Three Months Ended March 31, 2018 2017 Weighted average common shares outstanding – basic 718,803,900 401,283,532 Plus: Potentially dilutive common shares: Stock options and warrants 2,992,500 - Weighted average common shares outstanding – diluted 721,796,400 401,283,532 For the three months ended March 31, 2017, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Stock options and warrants excluded from the calculation of diluted EPS because their effect was anti-dilutive were 61,440,000 and 110,690,004 as of March 31, 2018 and 2017, respectively.
Stock-Based Compensation	Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company had no stock based compensation issuances during the three months ended March 31, 2018 and 2017.
Revenue Recognition	Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales commenced on July 5, 2017 with the termination of our joint venture and are recognized upon shipment of goods, which are typically paid for at the time of order.
Advertising and Promotion	All costs associated with advertising and promoting products are expensed as incurred. These expenses were $9,925 and $67,216 for the three months ended March 31, 2018 and 2017, respectively.
Income Taxes	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.
Uncertain Tax Positions	In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.
Recent Accounting Pronouncements	Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the three months ended March 31, 2018 and 2017, or the twelve months ended December 31, 2017. In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2017-09 , Compensation — Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-9 No other new accounting pronouncements, issued or effective during the three months ended March 31, 2018, have had or are expected to have a significant impact on the Company’s financial statements.

Basis of Presentation and Sig19

Basis of Presentation and Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Reconciliation of the denominators used to calculate basic EPS and diluted EPS	The reconciliation of the denominators used to calculate basic EPS and diluted EPS for the three months ended March 31, 2018 and 2017 are as follows: For the Three Months Ended March 31, 2018 2017 Weighted average common shares outstanding – basic 718,803,900 401,283,532 Plus: Potentially dilutive common shares: Stock options and warrants 2,992,500 - Weighted average common shares outstanding – diluted 721,796,400 401,283,532

Fair Value of Financial Instr20

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2018
Fair Value Of Financial Instruments Tables
Fair Value of Financial Instruments on Recurring Basis	The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of March 31, 2018 and December 31, 2017, respectively: Fair Value Measurements at March 31, 2018 Level 1 Level 2 Level 3 Assets Cash $ 79,221 $ - $ - Total assets 79,221 - - Liabilities Convertible notes payable 154,778 Derivative liabilities - - 1,574,343 Total liabilities - 154,778 1,574,343 $ 79,221 $ (154,778 ) $ (1,574,343 ) Fair Value Measurements at December 31, 2017 Level 1 Level 2 Level 3 Assets Cash $ 83,704 $ - $ - Total assets 83,704 - - Liabilities Convertible note payable, net of discounts - 169,990 - Derivative liabilities - - 2,255,781 Total liabilities - 169,990 2,255,781 $ 83,704 $ (169,990 ) $ (2,255,781 )

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2018
Convertible Notes Payable Tables
Summary of convertible note payable	March 31, December 31, 2018 2017 On March 1, 2018, the Company received proceeds of $30,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on May 31, 2018 (“First Red Diamond Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. $ 30,000 $ - On March 1, 2018, the Company received proceeds of $30,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on May 31, 2018 (“First SEG-RedaShex Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. 30,000 - On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second Diamond Rock Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default. 50,000 50,000 On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second SEG Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $10,000 of principal was converted into 5,208,333 shares of common stock on October 31, 2017, and the remaining $40,000 of principal was converted into 26,559,426 shares of common stock on January 29, 2018. - 40,000 On August 8, 2017, the Company entered into an exchange agreement with Diamond Rock, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First Diamond Rock Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $15,000 of principal was converted into an aggregate of 7,812,500 shares of common stock at various dates between November 6, 2017 and November 13, 2017. Currently in default. 35,000 35,000 On August 8, 2017, the Company entered into an exchange agreement with The Special Equities Group, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First SEG Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default. 50,000 50,000 On August 8, 2017, the Company entered into an exchange agreement with RDW Capital, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First RDW Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $25,000 of principal was converted into 13,157,895 shares of common stock on October 31, 2017, and the remaining $25,000 of principal was converted into 19,230,769 shares of common stock on January 3, 2018. - 25,000 Total convertible notes payable, currently in default 195,000 200,000 Less unamortized derivative discounts: 40,222 30,010 Convertible notes payable 154,778 169,990 Less: current portion 154,778 169,990 Convertible notes payable, less current portion $ - $ -
Recognized interest expense	March 31, March 31, 2018 2017 Interest on convertible notes $ 3,285 $ 2,691 Interest on related party loans 1,800 600 Derivative discounts 60,860 149,456 Total interest expense $ 64,145 $ 152,747

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	3 Months Ended
	Mar. 31, 2018
Derivative Liabilities Tables
Summary of Changes in fair market value Derivative Liability	The following is a summary of changes in the fair market value of the derivative liability during the three months ended March 31, 2018 and the year ended December 31, 2017, respectively: Derivative Liability Total Balance, December 31, 2016 $ 221,822 Increase in derivative value due to issuances of convertible promissory notes 221,515 Increase in derivative value attributable to tainted warrants 7,103,444 Decrease in derivative value attributable to exchange of warrants (3,766,437 ) Change in fair market value of derivative liabilities due to the mark to market adjustment (1,221,021 ) Debt conversions (303,542 ) Balance, December 31, 2017 $ 2,255,781 Increase in derivative value due to issuances of convertible promissory notes 71,072 Change in fair market value of derivative liabilities due to the mark to market adjustment (700,240 ) Debt conversions (52,270 ) Balance, March 31, 2018 $ 1,574,343

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2018
Income Taxes Tables
Deferred tax asset	The components of the Company’s deferred tax asset are as follows: March 31, December 31, 2018 2017 Deferred tax assets: Net operating loss carry forwards $ 1,725,000 $ 1,701,000 Net deferred tax assets before valuation allowance $ 1,725,000 $ 1,701,000 Less: Valuation allowance (1,725,000 ) (1,701,000 ) Net deferred tax assets $ - $ -
Reconciliation between the amounts of income tax	A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and state statutory income tax rate to pre-tax loss is as follows: March 31, December 31, 2018 2017 Federal and state statutory rate 21 % 35 % Change in valuation allowance on deferred tax assets (21) % (35) %

Basis of Presentation and Sig24

Basis of Presentation and Significant Accounting Policies (Details) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Notes to Financial Statements
Weighted average number of common shares outstanding - basic	718,803,900	401,283,532
Plus: Potentially dilutive common shares:
Stock options and warrants	2,992,500
Weighted average number of common shares outstanding - fully diluted	721,796,400	402,283,532

Basis of Presentation and Sig25

Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Basis Of Presentation And Significant Accounting Policies Details Narrative
Advertising and promotion expenses	$ 9,925	$ 67,216
Anti-dilutive shares	61,440,000	110,690,004

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Going Concern Details Narrative
Accumulated deficit	$ (15,762,488)	$ (16,328,812)
Working capital deficit	$ (1,934,048)

Related Parties (Details Narrat

Related Parties (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Board of Directors Chairman [Member]
Amount owed	$ 39,116	$ 40,195
Reimbursable expenses	1,075	478
Chief Executive Officer [Member]
Reimbursable expenses	$ 713	$ 713

Patent Rights and Applications

Patent Rights and Applications (Details Narrative)	3 Months Ended
	Mar. 31, 2018
Patents [Member]
Estimated useful life	17 years

Fair Value of Financial Instr29

Fair Value of Financial Instruments (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Assets
Cash	$ 79,221	$ 83,704	$ 209,885
Liabilities
Convertible note payable, net of discounts	154,778	169,990
Derivative liabilities	1,574,343	2,255,781		$ 221,822
Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Assets
Cash	79,221	83,704
Total assets	79,221	83,704
Liabilities
Convertible note payable, net of discounts
Derivative liabilities
Total liabilities
Net assets and liabilities	79,221	83,704
Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Assets
Cash
Total assets
Liabilities
Convertible note payable, net of discounts	154,778	169,990
Derivative liabilities
Total liabilities	154,778	169,990
Net assets and liabilities	(154,778)	(169,990)
Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Assets
Cash
Total assets
Liabilities
Convertible note payable, net of discounts
Derivative liabilities	1,574,343	2,255,781
Total liabilities	1,574,343	2,255,781
Net assets and liabilities	$ (1,574,343)	$ (2,255,781)

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Total convertible note payable	$ 195,000	$ 200,000
Less unamortized debt derivative discounts	40,222	30,010
Convertible note payable	154,778	169,990
Less: current portion	154,778	169,990
Convertible note payable, less current portion
On March 01 2018 First Red Diamond Note [Member]
Total convertible note payable	30,000
On March 01 2018 First SEG-RedaShex Note [Member]
Total convertible note payable	30,000
On October 30 2017 Second Diamond Rock Note [Member]
Total convertible note payable	50,000	50,000
On October 30 2017 Second SEG Note [Member]
Total convertible note payable		40,000
On August 8 2017 Diamond Rock LLC[Member]
Total convertible note payable	35,000	35,000
On August 8 2017 Special Equities Group LLC [Member]
Total convertible note payable	50,000	50,000
On August 8 2017 RDW Capital LLC [Member]
Total convertible note payable		$ 25,000

Convertible Notes Payable (De31

Convertible Notes Payable (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Convertible Notes Payable Details 1
Interest on convertible notes	$ 3,285	$ 2,691
Interest on related party loans	1,800	600
Derivative discounts	60,860	149,456
Total interest expense	$ 64,145	$ 152,747

Convertible Notes Payable (De32

Convertible Notes Payable (Details Narrative) - USD ($)	Mar. 01, 2018	Nov. 13, 2017	Oct. 30, 2017	Aug. 08, 2017	Jan. 03, 2017	Jan. 29, 2018	Oct. 31, 2017
Series B [Member] | Common Stock [Member]
Warrant to purchase shares				10,101,011
RDW Capital LLC [Member]
Interest rate				8.00%
Maturity date				Nov. 30, 2017
Debt conversion price description				The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Converted shares					19,230,769		13,157,895
Converted amount				$ 50,000	$ 25,000		$ 25,000
RDW Capital LLC [Member] | Series B [Member]
Warrant to purchase shares				13,333,334
Diamond Rock LLC [Member]
Interest rate				8.00%
Maturity date				Nov. 30, 2017
Debt conversion price description				The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Converted shares		7,812,500
Converted amount		$ 50,000
Diamond Rock LLC [Member] | Common Stock [Member]
Warrant to purchase shares				10,101,011
Diamond Rock LLC [Member] | Series A [Member]
Warrant to purchase shares				13,333,334
Special Equities Group LLC [Member]
Interest rate				8.00%
Maturity date				Nov. 30, 2017
Debt conversion price description				The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Converted amount				$ 50,000
Special Equities Group LLC [Member] | Common Stock [Member]
Warrant to purchase shares				10,101,011
Special Equities Group LLC [Member] | Series A [Member]
Warrant to purchase shares				13,333,334
Special Equities Group LLC [Member] | Series B [Member]
Warrant to purchase shares				13,333,334
Second SEG Note [Member]
Interest rate			8.00%
Maturity date			Jan. 31, 2018
Debt conversion price description			The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Converted shares			5,208,333			26,559,426
Converted amount			$ 10,000			$ 40,000
Proceeds from convertible promissory note			$ 50,000
Second Diamond Rock Note [Member]
Interest rate			8.00%
Maturity date			Jan. 31, 2018
Debt conversion price description			The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default.
Proceeds from convertible promissory note			$ 50,000
First SEG-RedaShex Note [Member]
Interest rate	8.00%
Maturity date	May 31, 2018
Debt conversion price description	The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Proceeds from convertible promissory note	$ 30,000
First Red Diamond Note [Member]
Interest rate	8.00%
Maturity date	May 31, 2018
Debt conversion price description	The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Proceeds from convertible promissory note	$ 30,000

Derivative Liabilities (Details

Derivative Liabilities (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Derivative Liabilities Details
Beginning Balance	$ 2,255,781	$ 221,822	$ 221,822
Increase in derivative value due to issuances of convertible promissory notes	71,072		221,515
Increase in derivative value attributable to tainted warrants			7,103,444
Decrease in derivative value attributable to exchange of warrants			(3,766,437)
Change in fair market value of derivative liabilities due to the mark to market adjustment	(700,240)	$ (4,945,782)	(1,221,021)
Debt conversions	(52,270)		(303,542)
Ending Balance	$ 1,574,343		$ 2,255,781

Derivative Liabilities (Detai34

Derivative Liabilities (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Derivative liabilities	$ 1,574,343		$ 2,255,781
Change in derivative liabilities	(700,240)	$ 5,100,091
Change in fair market value of derivative liabilities due to the mark to market adjustment	(700,240)	(4,945,782)	$ (1,221,021)
Change in fair market value attributable to the warrants	(718,750)	(147,088)
Change in fair market value on convertible notes adjustment	$ 18,510	$ 7,221
Convertible Debenture [Member] | Warrant [Member]
Maturity term	2 years
Increase in trading fees (monthly)	1.00%
Default event, Description	An event of default would occur -0-% of the time, increasing 2% per month to a maximum of 10%.
Fundamental transaction, Description	A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%.
Redeem notes, Description	The Company would redeem the notes -0-% of the time, increasing 1% per month to a maximum of 5%.
Exercisable target prices description	target prices of 3 to 5 times the projected reset price or higher.
Reset events description	Reset events were projected to occur by 3/31/18 and 12/31/18 – the reset provision ends 3/30/19 and the option expires 3/30/20.
Maturity description	The Holder would exercise the warrant at maturity in 2020 if the stock price was above the reset exercise price.
Convertible Debenture [Member] | Warrant [Member] | Minimum [Member]
Stock price	$ 0.0033
Stock price in percent	253.00%
Volatility	146.00%
Trading fees (monthly)	$ 968,718
Convertible Debenture [Member] | Warrant [Member] | Maximum [Member]
Stock price	$ 0.0063
Stock price in percent	191.00%
Volatility	313.00%
Trading fees (monthly)	$ 1,011,107

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	May 09, 2012	Oct. 31, 2017USD ($)Integer
Research and Development Agreements [Member]
Contractual obligations, amount payable		$ 326,336
Contractual obligations, initial payment		$ 22,211
Contractual obligations, frequency of periodic payment		Monthly
Contractual obligations, number of installments | Integer		28
Research and Development Agreements [Member] | Minimum [Member]
Contractual obligations, periodic payments		$ 5,000
Research and Development Agreements [Member] | Maximum [Member]
Contractual obligations, periodic payments		$ 20,000
Collaborative Patent License Agreements [Member]
Sales revenue gross	10.00%
Agreement term	5 years

Changes in Stockholders_ Equi36

Changes in Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)	Jan. 03, 2018	Jan. 29, 2018	Mar. 31, 2018	Dec. 31, 2017	Feb. 09, 2016
Preferred stock, par value			$ 0.001	$ 0.001
Preferred stock, authorized shares			10,000,000	10,000,000
Common stock, par value			$ 0.00001	$ 0.00001	$ 0.00001
Common stock, authorized shares			1,000,000,000	1,000,000,000	1,000,000,000
Subscriptions payable, shares			0	63,675,678
Subscriptions payable, value				$ 273,805
Series A Preferred Stock [Member]
Preferred stock, par value			$ 0.001
Preferred stock, authorized shares			2,000,000
Preferred Stock voting rights convertible description			Each share of Series A Preferred Stock is convertible, at the option of the holder thereof, at any time after the issuance of such share into one (1) fully paid and non-assessable share of Common Stock. Each outstanding share of Series A Preferred Stock is entitled to one hundred (100) votes per share on all matters to which the shareholders of the Corporation are entitled or required to vote.
First RDW Note [Member]
Debt conversion converted instrument, shares issued	19,230,769
Debt conversion converted amount	$ 25,000
Second SEG Note [Member]
Debt conversion converted instrument, shares issued		26,559,426
Debt conversion converted amount		$ 40,000

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carry forwards	$ 1,725,000	$ 1,701,000
Net deferred tax assets before valuation allowance	1,725,000	1,701,000
Less: Valuation allowance	(1,725,000)	(1,701,000)
Net deferred tax assets

Income Taxes (Details 1)

Income Taxes (Details 1)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Income Taxes Details 1
Federal and state statutory rate	21.00%	35.00%
Change in valuation allowance on deferred tax assets	(21.00%)	(35.00%)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Income Taxes Details Narrative
Federal net operating losses	$ (4,930,000)	$ (4,860,000)
Federal net operating losses expire	2,031

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - Securities purchase agreement [Member] - Two investors [Member]	1 Months Ended
	Apr. 24, 2018USD ($)
Proceeds from sale of convertible notes	$ 60,000
Interest rate	8.00%
Maturity date	May 31, 2018
Debt conversion price description	The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.